Elevation Oncology, Inc. (ELEV)
NASDAQ: ELEV · IEX Real-Time Price · USD
2.640
-0.030 (-1.12%)
At close: Jul 19, 2024, 4:00 PM
2.550
-0.090 (-3.41%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Elevation Oncology Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Elevation Oncology stock have an average target of 7.80, with a low estimate of 6.00 and a high estimate of 10. The average target predicts an increase of 195.45% from the current stock price of 2.64.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ELEV stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 3 | 3 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $7 | Buy | Reiterates | $7 | +165.15% | Jul 15, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $7 | Buy | Reiterates | $7 | +165.15% | Jun 28, 2024 |
| Piper Sandler | Piper Sandler | Buy Initiates $10 | Buy | Initiates | $10 | +278.79% | May 31, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Initiates $8 | Buy | Initiates | $8 | +203.03% | May 14, 2024 |
| Wedbush | Wedbush | Buy Reiterates $8 | Buy | Reiterates | $8 | +203.03% | May 3, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.93
from -1.34
EPS Next Year
-0.99
from -0.93
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 44.8M | 228.3M |
| Avg | n/a | n/a | n/a | 15.3M | 82.6M |
| Low | n/a | n/a | n/a | n/a | 5.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 1,389.9% |
| Avg | - | - | - | - | 439.4% |
| Low | - | - | - | - | -62.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.86 | -0.76 | -0.53 | -0.67 | -0.53 |
| Avg | -0.93 | -0.99 | -1.19 | -0.72 | -0.51 |
| Low | -0.99 | -1.29 | -1.76 | -0.75 | -0.49 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.